MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. [electronic resource]
Producer: 20191008Description: 719-729 p. digitalISSN:- 1748-7838
- Animals
- Benzimidazoles -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Colonic Neoplasms -- drug therapy
- Drug Resistance, Neoplasm -- genetics
- Female
- Heterografts
- Humans
- Loss of Function Mutation
- MAP Kinase Kinase 4 -- antagonists & inhibitors
- MAP Kinase Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Signaling System -- drug effects
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Prostatic Neoplasms -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.